R/S-(S)-3-((S)-2-Acetylamino-3-methyl-butyrylamino)-N-{(S)-1-[1-((S)-2-hydroxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-6-methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]-2-methyl-propyl}-succinamic acid

ID: ALA1835399

PubChem CID: 56680385

Max Phase: Preclinical

Molecular Formula: C31H43N5O10

Molecular Weight: 645.71

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N1CCc2cc(C)ccc2C1C(=O)N[C@H]1CC(=O)OC1O)C(C)C)C(C)C

Standard InChI:  InChI=1S/C31H43N5O10/c1-14(2)24(32-17(6)37)28(42)33-20(12-22(38)39)27(41)35-25(15(3)4)30(44)36-10-9-18-11-16(5)7-8-19(18)26(36)29(43)34-21-13-23(40)46-31(21)45/h7-8,11,14-15,20-21,24-26,31,45H,9-10,12-13H2,1-6H3,(H,32,37)(H,33,42)(H,34,43)(H,35,41)(H,38,39)/t20-,21-,24-,25-,26?,31?/m0/s1

Standard InChI Key:  MGIHOMZITTVQKS-QYKDOZOMSA-N

Molfile:  

     RDKit          2D

 46 48  0  0  0  0  0  0  0  0999 V2000
   15.7666   -4.9600    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.4341   -4.4723    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.1784   -3.6828    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   15.3516   -3.6841    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.0992   -4.4740    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.8616   -3.0129    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   17.2140   -4.7235    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   15.7633   -5.7870    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   15.0602   -6.2211    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.3876   -7.4864    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.2401   -7.5767    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9489   -7.1563    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.5235   -7.1723    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2500   -8.4017    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.6696   -7.5608    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3805   -7.1403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6795   -8.3857    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9686   -8.8062    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4003   -8.7901    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.0991   -7.5448    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.3706   -6.3153    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.8058   -7.1243    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.5266   -7.5287    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.7960   -6.2994    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.5365   -8.3536    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   11.5110   -5.8789    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.2330   -6.2849    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   11.5023   -5.0556    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   12.2354   -7.1083    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.9561   -7.5127    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.6648   -7.0924    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.9660   -8.3376    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.2551   -8.7581    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.6805   -8.7421    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.6649   -6.2674    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   14.4126   -8.3105    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.0888   -7.0454    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.3369   -5.8320    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   15.1421   -8.6952    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.8186   -7.4383    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.8403   -8.2601    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.5646   -8.6512    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.2637   -8.2222    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.2400   -7.3958    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.5151   -7.0103    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.9893   -8.6148    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  1  5  1  0
  4  6  2  0
  2  7  1  0
  1  8  1  1
 11 12  1  0
 11 13  1  0
 11 14  2  0
 12 15  1  0
 15 16  1  0
 15 17  1  6
 17 18  1  0
 17 19  1  0
 16 20  1  0
 16 21  2  0
 20 22  1  0
 22 23  1  0
 22 24  1  1
 23 25  2  0
 24 26  1  0
 26 27  1  0
 26 28  2  0
 23 29  1  0
 29 30  1  0
 30 31  1  0
 30 32  1  6
 32 33  1  0
 32 34  1  0
 31 10  1  0
 31 35  2  0
 10 36  1  0
 10 37  1  0
 36 39  1  0
 40 37  1  0
 37  9  1  0
  9  8  1  0
  9 38  2  0
 41 39  1  0
 40 41  2  0
 41 42  1  0
 42 43  2  0
 43 44  1  0
 44 45  2  0
 45 40  1  0
 43 46  1  0
M  END

Associated Targets(Human)

CASP2 Tchem Caspase-2 (173 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CASP3 Tchem Caspase-3 (3632 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Biocomponents

Calculated Properties

Molecular Weight: 645.71Molecular Weight (Monoisotopic): 645.3010AlogP: -0.57#Rotatable Bonds: 12
Polar Surface Area: 220.54Molecular Species: ACIDHBA: 9HBD: 6
#RO5 Violations: 2HBA (Lipinski): 15HBD (Lipinski): 6#RO5 Violations (Lipinski): 3
CX Acidic pKa: 4.27CX Basic pKa: CX LogP: -0.29CX LogD: -3.28
Aromatic Rings: 1Heavy Atoms: 46QED Weighted: 0.16Np Likeness Score: 0.24

References

1. Maillard MC, Brookfield FA, Courtney SM, Eustache FM, Gemkow MJ, Handel RK, Johnson LC, Johnson PD, Kerry MA, Krieger F, Meniconi M, Muñoz-Sanjuán I, Palfrey JJ, Park H, Schaertl S, Taylor MG, Weddell D, Dominguez C..  (2011)  Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors.,  19  (19): [PMID:21903398] [10.1016/j.bmc.2011.08.020]
2. Chen, Yi-Hua YH and 9 more authors.  2006-03-09  Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors.  [PMID:16509578]
3. Maillard, Michel C MC and 17 more authors.  2011-10-01  Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors.  [PMID:21903398]

Source